B. Riley Wealth Advisors Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

B. Riley Wealth Advisors Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 22.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,297 shares of the company’s stock after purchasing an additional 4,457 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Novo Nordisk A/S were worth $2,422,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its holdings in Novo Nordisk A/S by 184.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 73,193 shares of the company’s stock worth $8,156,000 after purchasing an additional 47,455 shares in the last quarter. Keybank National Association OH raised its holdings in shares of Novo Nordisk A/S by 11.1% during the 3rd quarter. Keybank National Association OH now owns 27,511 shares of the company’s stock worth $2,741,000 after acquiring an additional 2,755 shares in the last quarter. Old North State Trust LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $41,000. Canvas Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $211,000. Finally, Asset Dedication LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $96,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. JPMorgan Chase & Co. upped their price objective on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a report on Tuesday, January 3rd. Cowen upped their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. StockNews.com started coverage on Novo Nordisk A/S in a research report on Thursday. They set a “strong-buy” rating on the stock. Finally, Cowen boosted their target price on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $697.78.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $139.44 on Friday. The stock’s fifty day moving average is $139.97 and its two-hundred day moving average is $123.45. The company has a market capitalization of $315.55 billion, a PE ratio of 40.18, a price-to-earnings-growth ratio of 1.51 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.29. Novo Nordisk A/S has a 52 week low of $95.02 and a 52 week high of $145.94.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 4th. Shareholders of record on Monday, March 27th will be given a $1.1887 dividend. This represents a yield of 0.8%. The ex-dividend date is Friday, March 24th. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. Novo Nordisk A/S’s dividend payout ratio is 23.34%.

Novo Nordisk A/S Profile

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.